Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41

Rastogi, P; Tang, G; Hassan, S; Geyer, CE Jr; Aza, CA; Magrinat, GC; Suga, JM; Bear, HD; Baez-Diaz, L; Sarwar, S; Boileau, JF; Brufsky, AM; Shibata, HR; Bandos, H; Paik, S; Yothers, G; Swain, SM; Mamounas, EP; Wolmark, N

Rastogi, P (通讯作者)，NSABP Fdn Inc, Pittsburgh, PA 15212 USA.;Rastogi, P (通讯作者)，Univ Pittsburgh, UPMC Hillman Canc Ctr, Sch Med, Pittsburgh, PA 15260 USA.;Rastogi, P (通讯作者)，Magee Womens Hosp, Pittsburgh, PA 15213 USA.

BREAST CANCER RESEARCH AND TREATMENT, 2023; 199 (2): 243

Abstract

BackgroundThe primary aim of this randomized neoadjuvant trial in operable, HER2-positive breast cancer, was to determine the efficacy on pathologic c......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索